Selected Grants
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY-STAGE PARKINSON'S DISEASE
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2025 - 2031Biohaven BHV-8000
Clinical TrialPrincipal Investigator · Awarded by Biohaven Pharmaceuticals · 2025 - 2028A Phase 2, Randomized, Double-Blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults with Moderate Stage Parkinson's Disease
Clinical TrialPrincipal Investigator · Awarded by Asklepios BioPharmaceutical, Inc. · 2025 - 2028An Integrated Biomarker Approach to Personalized, Adaptive Deep Brain Stimulation in Parkinson Disease
ResearchInvestigator · Awarded by National Institute of Neurological Disorders and Stroke · 2023 - 2027A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients with Multiple System Atrophy
Clinical TrialPrincipal Investigator · Awarded by Teva Branded Pharmaceutical Products R&D, Inc · 2024 - 202658 Week Open-Label Trial of Tavapadon in PD (TemPo-4 Trial)
Clinical TrialPrincipal Investigator · Awarded by Cerevel Therapeutics · 2020 - 2025A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON'S DISEASE (TEMPO-1 TRIAL)
Clinical TrialPrincipal Investigator · Awarded by Cerevel Therapeutics · 2020 - 2024A Multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Pa
Clinical TrialPrincipal Investigator · Awarded by NeuroDerm, Ltd · 2019 - 2024A Double-Blind, Placebo-Controlled, Safety Tolerability and Pharmacokinetics Study in Parkinson¿s Disease Participants Treated with Carbidopa/Levodopa and NE3107 Phase 2a
Clinical TrialPrincipal Investigator · Awarded by BioVie, Inc · 2022 - 2023Scalar Closed-Loop STN/GPi DBS Based on Evoked and Spontaneous Potentials
ResearchInvestigator · Awarded by National Institutes of Health · 2017 - 2023Duke Parkinson's Disease and Movement Disorders Fellowship
FellowshipPrincipal Investigator · Awarded by Abbott Cardiovascular Systems, Inc. · 2021 - 2022Duke Parkinson's Disease and Movement Disorders Fellowship 2021-22
FellowshipPrincipal Investigator · Awarded by Medtronic Foundation · 2021 - 2022Jeff Cooney Boston Scientific
FellowshipPrincipal Investigator · Awarded by Boston Scientific Corporation · 2020 - 2021Mitochondrial DNA damage as a blood-based biomarker of early Parkinson's disease
ResearchCo Investigator · Awarded by Michael J. Fox Foundation for Parkinson's Research · 2017 - 2019PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF BTRX-246040 IN PARKINSON'S DISEASE SUBJECTS WITH MOTOR FLUCTUATIONS ( PROTOCOL NEP-PD-201)
Clinical TrialPrincipal Investigator · Awarded by BlackThorn Therapeutics · 2018 - 2019Protecting Neurodevelopment in Latino Migrant Children by Reduced Exposure to Organophosphate Pesticides
ResearchCo Investigator · Awarded by National Institutes of Health · 2017 - 2019A Phase 2a, Double-Blind, Placebo-Controlled, Two-Part Study To Investigate the Safety And Efficacy Of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor Fluctuations
Clinical TrialPrincipal Investigator · Awarded by Dart NeuroScience · 2017 - 2018A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's Disease (UBeyoNDU)
Clinical TrialPrincipal Investigator · Awarded by NeuroDerm, Ltd · 2017 - 2018A MultiCtr,OL,dosageranging study in early,untreated or stably treated subjects with Parkinson's PD to determine the safety,tolerability and PK of inj ofSER-214administered subcu once a week for two weeks after 0-2 weeks of dose titration.
Clinical TrialPrincipal Investigator · Awarded by Serina Therapeutics, Inc. · 2016 - 2017External Relationships
- AbbVie, Inc.
- Gerson Lehrman Group
- Medtronic Foundation
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.